Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05086393 · ClinicalTrials.gov registry record · Phase 4

Duloxetine RCT on Postop TKA Outcomes

A Phase 4 study, sponsored by Rush University Medical Center.

Completed
Registry status
Phase 4
Development phase
241
Enrollment target

NCT05086393: Completed Phase 4 study, sponsored by Rush University Medical Center.

NCT05086393 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 241 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05086393, a Phase 4 study, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
241 participants
Enrollment target

Study Summary

The aim of this study is to determine if duloxetine is associated with differences in post-operative pain, patient-reported outcome measures, and opioid consumption in patients undergoing primary total knee arthroplasty compared to patients who do not receive the medication. If so, duloxetine has the potential to become widely incorporated into the multi-modal analgesic regimen given to patients following knee replacements.

Primary Outcome

Measuring in morphine equivalents, collect daily data on opioid consumption for each participant

Interventions

  • DRUG Duloxetine
  • DRUG Placebos

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2021-11-01
Est. Completion 2025-07-23
Phase Phase 4
Rush University Medical Center

320 total trials

What the finished NCT05086393 record still lists

NCT05086393 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 2 interventions - of which Duloxetine is the first listed.

NCT05086393 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05086393 about?

NCT05086393 is a clinical study titled "Duloxetine RCT on Postop TKA Outcomes". The aim of this study is to determine if duloxetine is associated with differences in post-operative pain, patient-reported outcome measures, and opioid consumption in patients undergoing primary total knee arthroplasty compared to patients who do not receive the medication. If so, duloxetine has th...

What is the current status of trial NCT05086393?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 241 participants. The study started on 2021-11-01. Estimated completion is 2025-07-23.

What interventions are being tested in trial NCT05086393?

The interventions under investigation include: Duloxetine (DRUG), Placebos (DRUG).

Who is sponsoring clinical trial NCT05086393?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05086393's enrollment target sits among peer trials

241 360th of 2000 higher than 1,641 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01189786 · 241 participants · NA

    Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

  • NCT05050383 · 241 participants · NA

    DISE: Phenotyping Obstruction Patterns

  • NCT05683418 · 241 participants · Phase 1

    A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

  • NCT07213791 · 241 participants · Phase 1

    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05086393, the US trial registry maintained by the National Library of Medicine. NCT05086393 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.